Radio-immunotherapy

One of AECA's first scientific initiatives supported Russian and U.S. collaborative research to develop radiopharmaceuticals for the detection and treatment of cancer.

Pilot Study Development RIT Project:  Fox Chase scientists led studies with Russian research institutes to optimize the radiolabeling process and determine the ability of Iodine-124 labeled diabodies to localize human tumors growing in mouse models.

Pilot Study Development RIT Project: Fox Chase scientists led studies with Russian research institutes to optimize the radiolabeling process and determine the ability of Iodine-124 labeled diabodies to localize human tumors growing in mouse models.

Gregory+QUote.jpg

Through this partnership, Russian scientific partnering institutes provided reliable, cost-effective access to high-quality nuclear technology and medical radioisotopes to scientists at Fox Chase Cancer Center and premier, Maryland-based research facilities. Under the auspices of AECA, scientists successfully developed anti-tumor antibody markers for use in imaging technology detection, as well as refined the technique of staging of cancer using unique radionuclides.

The partnership between scientific collaborators has facilitated the development and production of next-generation antibody-based radiotracers, and generated multiple scientific abstract presentations and peer-reviewed journal publications covering the innovative use of radioisotopes in the detection and treatment of ovarian, renal, and breast cancers.